GDRX241115P10000
- 3.10
- 0.000.00%
GoodRx Newsroom
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $5
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings (GDRX) Receives a Buy From RBC Capital
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $16
Leerink Partners Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $12
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings: A Buy Rating on Strong Long-Term Care Growth and Strategic Market Positioning
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
Progyny Stock Sinks 25% After Losing a Big Client. Why This Analyst Still Likes the Stock. -- Barrons.com
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
GoodRx Holdings Analyst Ratings
RBC Capital Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
RBC Capital Keeps Their Buy Rating on GoodRx Holdings (GDRX)
GoodRx Holdings: A Hold Rating Amid Mixed Performance and Market Challenges
Analysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and UniQure (QURE)
GoodRx Holdings Analyst Ratings
GoodRx Holdings (GDRX) Gets a Buy From TD Cowen
Truist Financial Keeps Their Hold Rating on GoodRx Holdings (GDRX)